[ad_1]
Sufferers hospitalized with COVID-19 receiving supplemental oxygen had comparable mortality outcomes with high- vs standard-dose dexamethasone, however proof suggests larger dexamethasone doses could also be related to opposed outcomes. These examine outcomes have been introduced at IDWeek 2022, held from October 19 to 23, in Washington, DC.
Anti-inflammatory brokers, corresponding to dexamethasone, are normal remedy for COVID-19 an infection. Present proof signifies {that a} 6-mg dose of dexamethasone every day is efficient for bettering COVID-19 outcomes amongst sufferers receiving supplemental oxygen. Nonetheless, sufferers are sometimes prescribed larger doses regardless of a scarcity of proof justifying this scientific choice.
To judge whether or not larger doses of dexamethasone could also be more practical, researchers performed a multisite, retrospective, observational examine. Included sufferers have been those that have been hospitalized with COVID-19 an infection and receiving supplemental between June 2020 and January 2022. Sufferers who acquired high-dose dexamethasone (>10 mg every day; n=159) have been matched in a 3:1 vogue with those that acquired standard-dose dexamethasone (£6 mg every day; n=53); the researchers in contrast outcomes between the teams.
No important variations within the charge of mortality, the variety of sufferers with blood glucose concentrations above 200 mg/dL, the speed of nosocomial infections, hospitalization, or the variety of ventilator-free days (all P >.05) have been noticed on the idea of dexamethasone dosing.
“
This examine helps the usage of SD DEX in ventilated COVID-19 sufferers.
Comparable outcomes have been noticed after adjustment for potential confounding components, with no important variations noticed between the two affected person teams in regard to the chance for mortality (adjusted odds ratio [aOR], 1.45; 95% CI, 0.66-3.20).
Within the adjusted evaluation, nevertheless, receipt of high-dose dexamethasone was related to will increase in every day blood glucose concentrations (P =.003) and size of intensive care unit keep (P =.019) in contrast with receipt of standard-dose dexamethasone.
This examine was restricted by its small pattern dimension.
“This examine helps the usage of SD DEX [standard-dose dexamethasone] in ventilated COVID-19 sufferers,” the researchers concluded.
This text initially appeared on Infectious Illness Advisor.
References:
Kale-Pradhan P, Pacitto R, Krumm L, et al. Impact of high-dose versus standard-dose dexamethasone on mortality amongst mechanically ventilated COVID-19 sufferers. Offered at: IDWeek 2022; October 19-23; Washington, DC. Poster 1124.
[ad_2]
Source link